Related Experiment Videos

Sustained hemoconcentration in patients with chronic atrial fibrillation, a potential risk for stroke and

H Yamada1, T Sugiyama, T Ashida

  • 1Institute for Adult Diseases Asahi Life Foundation, Tokyo, Japan.

Japanese Heart Journal
|March 25, 1999
PubMed

Insights

Hemoconcentration, an increase in blood concentration, persists for at least four years after developing chronic atrial fibrillation. This sustained hemoconcentration may increase stroke risk.

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Hemoconcentration is observed during paroxysmal and early chronic atrial fibrillation.
  • The persistence of hemoconcentration after transition to chronic atrial fibrillation is not well-established.

Purpose of the Study:

  • To determine the duration of hemoconcentration following the transition from sinus rhythm to chronic atrial fibrillation.
  • To assess the long-term hematocrit levels in patients with chronic atrial fibrillation compared to controls.

Main Methods:

  • Retrospective observational study.
  • Involved 9 patients with chronic atrial fibrillation and 18 age- and gender-matched controls.
  • Hematocrit levels were monitored over a long-term period.

Main Results:

  • Hematocrit levels significantly increased from 44.88% to 46.87% upon transition to chronic atrial fibrillation (p < 0.01).
  • Elevated hematocrit levels persisted for at least 4 years in patients with chronic atrial fibrillation.
  • Hematocrit levels remained stable in the control group.
  • A significant difference in hematocrit was observed between chronic atrial fibrillation patients and controls (p < 0.001).

Conclusions:

  • Hemoconcentration is a persistent finding in chronic atrial fibrillation, lasting at least 4 years.
  • Sustained hemoconcentration in atrial fibrillation may pose a risk for stroke and thromboembolic complications.

Related Concept Videos